Uploaded May 2026 | Updated November 2026, 4 days ago
Whilst survival rates for childhood cancers have improved dramatically, treatment options for children and young people are limited due to the small populations of patients. Therefore, developing treatment methods can be challenging due to constraints generating robust evidence.
Professor Amos Burke, Professor of Paediatric Oncology at the University of Birmingham leads an international platform trial for children and young people with relapsed or refractory B-cell Hodgkin lymphoma. The trial, Glo BNHL, brings together global expertise through a single, flexible trial infrastructure, enabling multiple treatments to be tested within the same rare disease population.
Read the article to find out more about our paediatric cancer trials research: birmingham.ac.uk/news/2026/a-blueprint-for-faster-fairer-drug-development-in-rare-childhood-cancers
Whilst survival rates for childhood cancers have improved dramatically, treatment options for children and young people are limited due to the small populations of patients. Therefore, developing treatment methods can be challenging due to constraints generating robust evidence.
Professor Amos Burke, Professor of Paediatric Oncology at the University of Birmingham leads an international platform trial for children and young people with relapsed or refractory B-cell Hodgkin lymphoma. The trial, Glo BNHL, brings together global expertise through a single, flexible trial infrastructure, enabling multiple treatments to be tested within the same rare disease population.
Read the article to find out more about our paediatric cancer trials research: birmingham.ac.uk/news/2026/a-blueprint-for-faster-fairer-drug-development-in-rare-childhood-cancers










